FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccine / Safety and efficacy in geese of a PER.C6-based inactivated W...
Vaccine2007; 25(49); 8338-8345; doi: 10.1016/j.vaccine.2007.09.055

Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.

Abstract: Studies were performed with an inactivated vaccine against the mosquito-borne flavivirus, West Nile virus (WNV). The mammalian cell line, PER.C6, was selected as the platform for WNV growth since both the neurovirulent strains NY99 and ISR98 that cause epidemics in humans and high mortality in geese, respectively, could be propagated to high titers (10(9) to 10(10)TCID(50)/ml) on these cells. Based on the high DNA homology of the WNV envelope (E) protein and non-structural protein 5 (NS5), and identical neurovirulence in mice and geese, we concluded that NY99 and ISR98 viruses are closely related and therefore vaccine studies were performed with ISR98 as a model for NY99. A robust challenge model in domestic geese was set up resulting in 100% mortality within 7 days of intracranial challenge with 500 TCID(50) WNV. Geese were used to assess the efficacy and safety of an inactivated WNV vaccine produced on PER.C6 cells. Efficacy studies demonstrated 91.4% (53/58) protection of geese compared to no protection (0/13) in geese receiving a sham vaccine. A follow-up study in 1800 geese showed that the vaccine was safe with a survival rate of 96.6% (95% lower CL 95.7%). Initial studies on the correlates of protection induced by the vaccine indicate an important role for antibodies since geese were protected when injected intra-cranial with a mixture of serum from vaccinated, non-challenged geese and WNV. In all, these results provide a scientific basis for the development of an inactivated WNV vaccine based on NY99 produced on PER.C6 cells for human and equine use.
Get Full Text
Publication Date: 2007-10-15 PubMed ID: 17977629DOI: 10.1016/j.vaccine.2007.09.055Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses a study on the safety and effectiveness of a PER.C6-based inactivated West Nile Virus (WNV) vaccine in geese.

Introduction

  • In this research, the team examined the safety and effectiveness of a vaccine against West Nile virus (WNV), a flavivirus that is spread by mosquitos.
  • The team chose the PER.C6 mammalian cell line as the growth platform for WNV because it allows for the propagation of high titers of two strains of the virus, NY99 and ISR98, that are responsible for human epidemics and high goose mortality, respectively.

Methodology

  • The team identified the high degree of DNA homology in the envelope (E) protein and non-structural protein 5 (NS5) as well as the identical neurovirulence in mice and geese of the NY99 and ISR98 strains.
  • Given these similarities, they concluded that the two strains are closely related and opted to perform vaccine studies using ISR98 as a model for NY99.
  • The team developed a robust challenge model in domestic geese that resulted in 100% mortality within 7 days of intracranial challenge with 500 TCID(50) WNV.

Efficacy and Safety Assessment

  • The safety and efficacy of the inactivated WNV vaccine produced on PER.C6 cells were assessed in geese.
  • Results from the study showed a 91.4% (53/58) protection rate in geese compared to no protection (0/13) in geese that received a sham vaccine.
  • A subsequent study involving 1800 geese revealed that the vaccine is safe, with a survival rate of 96.6% (95% lower CL 95.7%).

Correlation Study between Vaccine and Protection

  • Initial studies into the correlates of protection induced by the vaccine pointed to the significant role of antibodies.
  • Evidence of this was found when geese that were injected intracranially with a mixture of serum from vaccinated, non-challenged geese and WNV were protected.

Conclusion

  • In conclusion, the results of this research provide a scientific basis for creating an inactivated WNV vaccine based on NY99 and produced on PER.C6 cells for use in humans and horses.

Cite This Article

APA
Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, Simanov M, Perl S, Gijsbers L, Weverling GJ, Uytdehaag F, Goudsmit J. (2007). Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. Vaccine, 25(49), 8338-8345. https://doi.org/10.1016/j.vaccine.2007.09.055

Publication

Vaccine
ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 25
Issue: 49
Pages: 8338-8345

Researcher Affiliations

Samina, Itzchak
  • Kimron Veterinary Institute, PO Box 12, Bet Dagan 50250, Israel.
Havenga, Menzo
    Koudstaal, Wouter
      Khinich, Yevgeny
        Koldijk, Martin
          Malkinson, Mertyn
            Simanov, Michael
              Perl, Shmuel
                Gijsbers, Linda
                  Weverling, Gerrit Jan
                    Uytdehaag, Fons
                      Goudsmit, Jaap

                        MeSH Terms

                        • Animals
                        • Animals, Suckling
                        • Cell Line
                        • Geese / virology
                        • Humans
                        • Lethal Dose 50
                        • Mice
                        • Poultry Diseases / prevention & control
                        • Poultry Diseases / virology
                        • Retina / cytology
                        • Treatment Outcome
                        • Vaccines, Inactivated / administration & dosage
                        • Vaccines, Inactivated / adverse effects
                        • Vaccines, Inactivated / immunology
                        • Vaccines, Inactivated / therapeutic use
                        • Virus Replication
                        • West Nile Fever / mortality
                        • West Nile Fever / prevention & control
                        • West Nile Fever / veterinary
                        • West Nile Fever / virology
                        • West Nile Virus Vaccines / administration & dosage
                        • West Nile Virus Vaccines / adverse effects
                        • West Nile Virus Vaccines / immunology
                        • West Nile Virus Vaccines / therapeutic use
                        • West Nile virus / immunology
                        • West Nile virus / physiology

                        Citations

                        This article has been cited 13 times.
                        1. Holicki CM, Michel F, Vasić A, Fast C, Eiden M, Răileanu C, Kampen H, Werner D, Groschup MH, Ziegler U. Pathogenicity of West Nile Virus Lineage 1 to German Poultry.. Vaccines (Basel) 2020 Sep 5;8(3).
                          doi: 10.3390/vaccines8030507pubmed: 32899581google scholar: lookup
                        2. Jiménez de Oya N, Escribano-Romero E, Blázquez AB, Martín-Acebes MA, Saiz JC. Current Progress of Avian Vaccines Against West Nile Virus.. Vaccines (Basel) 2019 Sep 23;7(4).
                          doi: 10.3390/vaccines7040126pubmed: 31547632google scholar: lookup
                        3. Wang J, Yang J, Ge J, Hua R, Liu R, Li X, Wang X, Shao Y, Sun E, Wu D, Qin C, Wen Z, Bu Z. Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry.. Virol J 2016 Jun 24;13:109.
                          doi: 10.1186/s12985-016-0568-5pubmed: 27342050google scholar: lookup
                        4. Acharya D, Bai F. An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection.. Methods Mol Biol 2016;1435:249-91.
                          doi: 10.1007/978-1-4939-3670-0_19pubmed: 27188563google scholar: lookup
                        5. Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN. A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations.. PLoS One 2016;11(2):e0149610.
                          doi: 10.1371/journal.pone.0149610pubmed: 26901122google scholar: lookup
                        6. Fischer D, Angenvoort J, Ziegler U, Fast C, Maier K, Chabierski S, Eiden M, Ulbert S, Groschup MH, Lierz M. DNA vaccines encoding the envelope protein of West Nile virus lineages 1 or 2 administered intramuscularly, via electroporation and with recombinant virus protein induce partial protection in large falcons (Falco spp.).. Vet Res 2015 Aug 17;46(1):87.
                          doi: 10.1186/s13567-015-0220-1pubmed: 26282836google scholar: lookup
                        7. Oosterhoff D, van de Weerd G, van Eikenhorst G, de Gruijl TD, van der Pol LA, Bakker WA. Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1.. Biomed Res Int 2015;2015:358462.
                          doi: 10.1155/2015/358462pubmed: 25815312google scholar: lookup
                        8. Jordan I, Sandig V. Matrix and backstage: cellular substrates for viral vaccines.. Viruses 2014 Apr 11;6(4):1672-700.
                          doi: 10.3390/v6041672pubmed: 24732259google scholar: lookup
                        9. Angenvoort J, Fischer D, Fast C, Ziegler U, Eiden M, de la Fuente JG, Lierz M, Groschup MH. Limited efficacy of West Nile virus vaccines in large falcons (Falco spp.).. Vet Res 2014 Apr 7;45(1):41.
                          doi: 10.1186/1297-9716-45-41pubmed: 24708385google scholar: lookup
                        10. Amanna IJ, Slifka MK. Current trends in West Nile virus vaccine development.. Expert Rev Vaccines 2014 May;13(5):589-608.
                          doi: 10.1586/14760584.2014.906309pubmed: 24689659google scholar: lookup
                        11. Brandler S, Tangy F. Vaccines in development against West Nile virus.. Viruses 2013 Sep 30;5(10):2384-409.
                          doi: 10.3390/v5102384pubmed: 24084235google scholar: lookup
                        12. Iyer AV, Kousoulas KG. A review of vaccine approaches for West Nile virus.. Int J Environ Res Public Health 2013 Sep 10;10(9):4200-23.
                          doi: 10.3390/ijerph10094200pubmed: 24025396google scholar: lookup
                        13. Gershoni-Yahalom O, Landes S, Kleiman-Shoval S, Ben-Nathan D, Kam M, Lachmi BE, Khinich Y, Simanov M, Samina I, Eitan A, Cohen IR, Rager-Zisman B, Porgador A. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge.. Immunology 2010 Aug;130(4):527-35.
                          doi: 10.1111/j.1365-2567.2010.03251.xpubmed: 20331473google scholar: lookup
                        Subscribe to our newsletter
                        Join 99,105 horse owners like you who receive our email updates on horse health and nutrition.